What Is the G0121 CPT Code?
G0121 is a Medicare HCPCS Level II code that reports a screening colonoscopy for an average-risk patient, meaning someone with no personal or family history that raises their colorectal cancer risk. It is the code Medicare requires instead of a standard CPT colonoscopy code when the visit is preventive. Used correctly, it delivers the screening to the patient at zero out-of-pocket cost.
It is HCPCS, not CPT: Providers search for the G0121 CPT code, but G0121 is a HCPCS Level II code. Billing CPT 45378 to Medicare instead is one of the most common screening denials in gastroenterology billing.
Average risk only, starting at age 45: G0121 covers patients who are not high risk. High-risk beneficiaries use G0105, and choosing the wrong one triggers a frequency or medical-necessity denial. Under the Consolidated Appropriations Act of 2023, Medicare lowered the screening eligibility age from 50 to 45 for average-risk beneficiaries.
Zero cost when it stays preventive: Under the Affordable Care Act, Medicare waives both the deductible and coinsurance for G0121, but that protection changes the moment a polyp is removed. A specialized gastroenterology billing service tracks these conversion rules across payers so your practice does not bill the patient incorrectly.
Why Is G0121 a HCPCS Code and Not a CPT Code?
G0121 is a HCPCS Level II code because CMS created a separate G-code series to distinguish preventive screening colonoscopies from diagnostic ones in the Medicare population. A standard CPT code like 45378 does not signal screening intent to Medicare, so submitting it for an average-risk screening produces a denial or inappropriately bills the patient.
Most billing teams learn colonoscopy coding through the CPT 45378 to 45398 family, so the instinct is to reach for the diagnostic colonoscopy code on every colonoscopy. For commercial and Medicaid plans that instinct is correct. For Medicare it is a mistake. The most common issue we see providers run into is billing CPT 45378 to Medicare for an average-risk screen, which strips the patient’s preventive protection and bounces the claim. CMS built G0105 and G0121 specifically so its systems can tell a screening apart from a workup, and the American Gastroenterological Association confirms the G-code is the required code for a Medicare screening, not the CPT code. The distinction is not cosmetic. It controls whether the patient’s preventive cost-sharing waiver applies.
The MUE (Medically Unlikely Edit) for G0121 is 1 per date of service with an MAI of 2, per the CMS NCCI MUE table for Q2 2026. A practice cannot bill more than one screening colonoscopy on the same date, and the MAI 2 designation means the edit is applied at the claim line level. This is rarely a practical issue for a standalone screening, but it matters when the conversion to a therapeutic code occurs and both the G-code and the therapeutic CPT appear on the same claim in error.
When Should You Use G0121 vs G0105 vs 45378?
Use G0121 for an average-risk Medicare screening, G0105 for a high-risk Medicare screening, and CPT 45378 for a diagnostic colonoscopy or a commercial-plan screening. Risk status and payer, not the procedure itself, drive the code. The single most expensive error is billing a diagnostic CPT code for a Medicare patient who arrived for a preventive screen.
| Clinical scenario | Correct code | Key modifier |
| Average-risk Medicare screening | G0121 | KX if after positive stool test |
| High-risk Medicare screening | G0105 | KX if after positive stool test |
| Medicare screening, polyp removed | 45385 (or 45380/45384) | PT |
| Commercial or Medicaid screening | 45378 | 33 |
| Diagnostic or symptomatic colonoscopy | 45378 | None (diagnosis-driven) |
High risk is not a judgment call. It requires documentation such as a family history of colorectal cancer, a personal history of adenomatous polyps or colorectal cancer, or inflammatory bowel disease. Billing G0105 without that support in the record is upcoding. Clinically, the U.S. Preventive Services Task Force recommends average-risk screening begin at age 45, and commercial plans follow that preventive mandate. Under 42 CFR Section 410.37, high risk includes a personal history of CRC or adenomatous polyps, a family history of CRC or advanced adenoma in a first-degree relative before age 60 (or in two or more first-degree relatives at any age), or a hereditary syndrome such as FAP or HNPCC.
How Much Does Medicare Pay for G0121 in 2026?
In 2026, Medicare’s national average allowed amount for G0121 is roughly $675 in an ambulatory surgery center and about $1,115 in a hospital outpatient department, with the physician’s professional fee billed separately. Because the service is preventive, the patient pays none of it when no polyp is found.
| Setting | 2026 allowed amount | Patient cost, clean screening |
| Ambulatory surgery center (ASC) | $675 | $0 |
| Hospital outpatient department | $1,115 | $0 |
These figures come from Medicare’s 2026 Procedure Price Lookup and reflect facility allowances only. On the professional side, payment follows the CY 2026 Physician Fee Schedule Final Rule (CMS-1832-F), which set the non-qualifying conversion factor at $33.42 and applied a 2.5 percent efficiency reduction to the work RVUs on high-volume procedure codes, including high-volume endoscopy. Practices running large colonoscopy panels should model the combined hit: a lower conversion factor and a work-RVU trim compress margins on exactly the codes a GI practice bills most. The 2027 Medicare GI payment changes propose further reductions, making accurate coding on every screening even more critical to revenue protection.
The Modifiers That Make or Break a G0121 Claim
Three modifiers decide whether a G0121 claim pays cleanly, and each one answers a different question for the payer. Getting them wrong is the difference between a paid claim and an unprocessable one.
Modifier PT (screening converted to diagnostic). Append PT to the therapeutic CPT code, never to G0121 itself, when the endoscopist acts on a finding, whether that is a colonoscopy with biopsy (45380) or a snare polypectomy (45385). PT tells Medicare the encounter began as a screening, which preserves the patient cost-sharing protection. Per First Coast and Noridian guidance, it belongs on at least one surgical-range code on the claim.
Modifier 33 (preventive services). This is the commercial and Medicaid equivalent of PT. Add modifier 33 to the colonoscopy code on non-Medicare screening claims so the plan applies the ACA zero-cost-share mandate. Do not add 33 to a Medicare claim that already carries PT; the ASGE warns against stacking the two, because for Medicare, PT alone is sufficient.
Modifier KX (colonoscopy after a positive stool test). When the colonoscopy follows a positive non-invasive test such as a fecal immunochemical test, guaiac FOBT, multi-target stool DNA test, or the newly Medicare-covered ColoSense mt-sRNA test (covered under the June 2026 NCD revision), Medicare requires KX on the screening G-code. Omit it and Medicare returns the claim as unprocessable. This modifier also exempts the colonoscopy from the standard 10-year frequency limit, because it is part of the complete CRC screening continuum.
Modifier 53 (discontinued procedure). When a colonoscopy cannot be completed, the physician appends modifier 53 and the facility or ASC uses 74, with the billed amount reduced on submission. That is distinct from reduced services (modifier 52), which reports a service intentionally performed to a lesser extent rather than one stopped for patient safety.
How Does a Screening Colonoscopy Become Diagnostic?
A screening colonoscopy becomes diagnostic the moment the gastroenterologist acts on a finding, most often by removing a polyp or taking a biopsy. The intent that started the visit was preventive, so Medicare keeps part of the screening benefit: the deductible stays waived, but a reduced coinsurance now applies to the converted service.
This conversion is where patients get surprised and practices get denials. Medicare is phasing out the coinsurance a patient owes when a screening converts, so the penalty for finding a polyp shrinks each cycle. From 2023 through 2026, the patient owes a reduced 15 percent coinsurance on the converted service instead of the standard 20 percent. That share drops to 10 percent for 2027 through 2029 and disappears entirely in 2030, when converted screenings will be covered at 100 percent. The deductible is waived throughout.
| Dates of service | Patient coinsurance | Deductible |
| 2023 to 2026 | 15% | Waived |
| 2027 to 2029 | 10% | Waived |
| 2030 and later | 0% | Waived |
When a polyp is removed, the pathology lab bills separately under CPT 88305 for the tissue examination. The MUE for 88305 is 16, meaning up to 16 specimen jars can be billed per date of service. This pathology charge is billed on a separate claim by the lab, not bundled with the procedure code. Patients who expected a $0 screening sometimes receive a surprise pathology bill. Practices that explain the possibility of a separate pathology charge at scheduling, not after the statement prints, protect both collections and patient trust.
Colonoscopy conversions, phase-down coinsurance, and payer-specific modifier rules are exactly where gastroenterology claims leak revenue. In our experience matching providers with billing partners, the practices that audit their PT, KX, and 33 logic before submission are the ones that keep screening denials near zero. Get matched with vetted GI billing companies in about 30 minutes, at no cost to your practice.
Which ICD-10 Codes Pair With G0121?
The primary diagnosis for a G0121 screening is Z12.11, encounter for screening for malignant neoplasm of colon. Supporting codes include Z80.0 for a family history of digestive-organ cancer and the Z86.0100 series for a personal history of colon polyps. A mismatch between the G-code and its diagnosis triggers an automatic denial.
Medicare adjudicates the G-code and its ICD-10 code together, so the diagnosis has to support screening intent. Z12.11 is the workhorse. For a high-risk patient billed under G0105, add the code that justifies the elevated risk, such as Z80.0. Surveillance patients with a personal history of polyps are where teams still get tripped up. The old header code Z86.010 is no longer billable on its own. Since the October 2024 code update it requires a fifth character: Z86.0100 for unspecified polyps, Z86.0101 for adenomatous and serrated polyps, Z86.0102 for hyperplastic polyps, and Z86.0109 for other colon polyps. Across the billing companies we vet, that fifth-character catch is one of the quietest denial sources in GI billing, because the truncated code looks right at a glance. When a polyp is removed during the screen, add the finding code for the pathology, for example D12.6 for a benign neoplasm of the colon.
G0121 Frequency Rules and Screening Eligibility
Medicare covers G0121 once every 120 months (10 years) for average-risk beneficiaries, or once every 48 months after a prior screening flexible sigmoidoscopy. Submitting G0121 inside that window generates an automatic frequency denial. The Consolidated Appropriations Act of 2023 lowered the minimum screening age from 50 to 45 for average-risk beneficiaries under 42 CFR Section 410.37, aligning Medicare with the USPSTF recommendation. High-risk patients on G0105 qualify every 24 months.
The frequency limit does not apply when the colonoscopy follows a positive non-invasive CRC screening test. When a patient has a positive FIT, FOBT, multi-target stool DNA test (such as Cologuard), or the newly covered ColoSense mt-sRNA test, the follow-up colonoscopy is treated as part of the complete CRC screening continuum, and KX on the claim signals that relationship to Medicare. This distinction matters for gastroenterology billing services managing high-volume screening panels, because incorrectly triggering a frequency denial on a follow-up colonoscopy after a positive stool test is a recoverable error that should never happen with proper workflow.
How Do You Prevent the Most Common G0121 Denials?
Most G0121 denials come from a handful of repeatable errors: the wrong code family, a missed frequency window, a dropped modifier, or a stale diagnosis code. Catching them before submission is far cheaper than appealing them afterward. The seven checks below prevent the overwhelming majority of screening-colonoscopy rejections.
1. Confirm the payer before you code. Bill G0121 for Medicare and CPT 45378 with modifier 33 for commercial and Medicaid screenings.
2. Check the 10-year frequency window. Medicare denies a G0121 submitted within 120 months of a prior screening colonoscopy, so verify the last screening date before you file.
3. Document high risk before choosing G0105. Reserve G0105 for patients with a recorded family history, personal polyp history, or inflammatory bowel disease, because billing it without support is upcoding.
4. Append modifier KX after any positive stool test. Add KX to the screening G-code when the colonoscopy follows a positive FIT, FOBT, or stool DNA result, or the claim returns unprocessable.
5. Move to a therapeutic CPT code with PT when a polyp is removed. Report the procedure actually performed, such as 45385, and attach modifier PT rather than leaving G0121 in place.
6. Use the fifth-character polyp-history code. Replace the non-billable Z86.010 header with Z86.0100 through Z86.0109 on surveillance claims.
7. Bill sedation with the correct code. Report Medicare moderate sedation with G0500, and separate anesthesia with 00812 for a screening or 00811 with PT once the service converts.
What Does a G0121 Screening Cost When a Polyp Is Found?
When a polyp is found during a G0121 screening, the visit converts and the patient’s share changes from zero to a 15 percent coinsurance on the therapeutic portion in 2026. The deductible is still waived, but the free screening the patient expected now carries a balance they were never warned about.
Walk through a real 2026 example. An average-risk Medicare patient books a screening colonoscopy at an ASC. If the exam is clean, the practice reports G0121, Medicare covers the roughly $675 facility allowance in full, and the patient pays nothing. Change one detail: the gastroenterologist finds and snares a single polyp. The facility line becomes 45385 with modifier PT, the pathology supports D12.6, and although the deductible stays waived, the patient now owes 15 percent coinsurance on the converted service. The pathology lab then bills 88305 separately for the tissue exam, creating an additional charge the patient may not expect. One polyp is the difference between a $0 statement and a coinsurance balance plus a pathology bill. Practices that explain this possibility at scheduling, not after the statement prints, protect both collections and patient trust, and that pre-visit script is one of the highest-return process fixes a GI front desk can put in place.
Why Gastroenterology Billing Services Matter for Screening Colonoscopies
G0121 sits at the intersection of preventive care rules, payer-specific modifier logic, frequency edits, and conversion billing, which makes it one of the most denial-prone codes in gastroenterology. A generalist billing company that handles dermatology, cardiology, and GI all the same way will miss the screening-to-diagnostic conversion rules, misapply PT versus 33, or bill an incomplete colonoscopy under the wrong modifier. The result is denied claims, incorrect patient balances, and preventive cost-sharing protections that never get applied.
Providers often come to us after months of watching screening denials climb without understanding why. The pattern is almost always the same: the billing team is using CPT 45378 for Medicare screenings instead of G0121, or applying modifier 33 to Medicare claims instead of PT, or missing the KX modifier on follow-up colonoscopies after positive stool tests. These are not obscure edge cases. They are the daily coding decisions that a gastroenterology billing company handles by default and a generalist handles by accident.
For practices considering outsourced gastroenterology medical billing, the G0121 workflow is a useful litmus test. Ask any prospective billing partner how they handle a Medicare screening colonoscopy that converts when a polyp is found: which code replaces G0121, which modifier goes on it, what happens to the patient’s cost-sharing, and how the pathology gets billed. The quality of that answer tells you whether they know GI billing or merely list it among their specialties.
Frequently Asked Questions
Is G0121 a CPT or HCPCS code?
G0121 is a HCPCS Level II code, not a CPT code. Providers commonly search for the G0121 CPT code, but CMS maintains it in the HCPCS G-code series to flag Medicare screening colonoscopies. For commercial and Medicaid screenings, CPT 45378 with modifier 33 applies instead.
What is the difference between G0121 and G0105?
G0121 reports a screening colonoscopy for an average-risk Medicare patient, while G0105 reports one for a high-risk patient. High risk requires documentation such as a family history of colorectal cancer, a personal history of polyps, or inflammatory bowel disease. High-risk patients qualify every 24 months; average-risk patients every 10 years.
Does G0121 require modifier 33?
No. Modifier 33 is for commercial and Medicaid preventive claims, not Medicare. On a Medicare screening that converts to diagnostic, modifier PT applies instead, and PT should not be combined with 33. Adding 33 to a Medicare G0121 claim can cause the screening to be misprocessed.
What ICD-10 code is used with G0121?
The primary ICD-10 code for a G0121 screening is Z12.11, encounter for screening for malignant neoplasm of colon. High-risk claims add a code such as Z80.0, and surveillance claims use the Z86.0100 series for a personal history of polyps. The diagnosis must support screening intent.
How often will Medicare pay for G0121?
Medicare covers G0121 once every 120 months, or 10 years, for average-risk beneficiaries, or 48 months after a screening flexible sigmoidoscopy. Submitting G0121 inside that window generates an automatic frequency denial. The limit does not apply to follow-up colonoscopies after a positive stool test when KX is appended.
What happens if a polyp is removed during a G0121 screening?
The screening converts to a therapeutic service. Report the procedure performed, such as 45385 for a snare polypectomy, and append modifier PT so Medicare recognizes the screening origin. The deductible stays waived, but a reduced coinsurance of 15 percent applies through 2026, phasing to zero by 2030.
What age can a patient get a G0121 screening?
Under the Consolidated Appropriations Act of 2023, Medicare lowered the screening colonoscopy eligibility age from 50 to 45 for average-risk beneficiaries, aligning with the USPSTF recommendation. There is no minimum age requirement stated in the Medicare benefit, but the clinical screening recommendation begins at age 45.
How is pathology billed after a G0121 polyp removal?
The pathology lab bills separately under CPT 88305 for tissue examination. This charge is not bundled with the colonoscopy procedure code and appears on a separate claim from the laboratory. Up to 16 specimen jars (MUE of 16) can be billed per date of service. Patients often receive this bill separately from the facility and physician charges.
Next Steps
For a complete breakdown of how to bill the diagnostic colonoscopy code across all payers, see our guide on CPT code 45378.
To understand how the proposed 2027 Medicare GI payment changes will affect your colonoscopy reimbursement, including the conversion factor decrease and same-day E/M payment reduction, review our trending analysis.
If screening denials are eating your revenue, stop guessing and get matched with a billing company that specializes in gastroenterology.
G0121 is one code in a GI code set full of conversion rules, frequency edits, and payer-specific modifier logic that decide whether your practice gets paid. If screening-colonoscopy denials are eating your revenue, stop guessing and get matched with a billing company that specializes in gastroenterology. Billing Service Quotes reviews your practice by hand and connects you with vetted partners in about 30 minutes, with rates starting as low as 2.95 percent and no cost to request quotes.
